Abstract
The field of erectile dysfunction continues to evolve. Updated AUA Erectile Dysfunction Guidelines and the second Princeton Consensus Panel Guidelines, as well as updates regarding the oral PDE-5 inhibitors, are the focus of this article.
MeSH terms
-
Administration, Oral
-
Androgens / adverse effects
-
Androgens / therapeutic use
-
Cardiovascular Diseases / complications
-
Cardiovascular Diseases / diagnosis
-
Drug Therapy, Combination
-
Erectile Dysfunction / diagnosis*
-
Erectile Dysfunction / epidemiology
-
Erectile Dysfunction / etiology
-
Erectile Dysfunction / therapy*
-
Humans
-
Male
-
Medical History Taking
-
Penile Prosthesis
-
Phosphodiesterase Inhibitors / pharmacology
-
Phosphodiesterase Inhibitors / therapeutic use
-
Physical Examination
-
Practice Guidelines as Topic
-
Prevalence
-
Risk Assessment
-
Risk Factors
-
Safety
-
Testosterone / adverse effects
-
Testosterone / deficiency
-
Testosterone / therapeutic use
-
Vasodilator Agents / pharmacology
-
Vasodilator Agents / therapeutic use
Substances
-
Androgens
-
Phosphodiesterase Inhibitors
-
Vasodilator Agents
-
Testosterone